Curis | CRIS - Operating Profit


Curis reported $-11.52M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bayer EUR 827M 2.7B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
CSL USD 2.64B 1.97B Dec/2025
Curis USD -11.52M 3.64M Mar/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 248.41M 2.93M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Incyte USD 700.4M 376.22M Jun/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
Takeda JPY 201.42B 215.04B Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Verastem USD -44.9M 3.42M Mar/2026